MX2012002621A - Un metodo de cristalizacion de clorhidrato de (s)-n-metil-3-(1-naftiloxi)-3-(2-tienil)propilamina (duloxetina). - Google Patents

Un metodo de cristalizacion de clorhidrato de (s)-n-metil-3-(1-naftiloxi)-3-(2-tienil)propilamina (duloxetina).

Info

Publication number
MX2012002621A
MX2012002621A MX2012002621A MX2012002621A MX2012002621A MX 2012002621 A MX2012002621 A MX 2012002621A MX 2012002621 A MX2012002621 A MX 2012002621A MX 2012002621 A MX2012002621 A MX 2012002621A MX 2012002621 A MX2012002621 A MX 2012002621A
Authority
MX
Mexico
Prior art keywords
duloxetine
thienyl
methyl
phthyloxy
crystallization
Prior art date
Application number
MX2012002621A
Other languages
English (en)
Spanish (es)
Inventor
Ludek Ridvan
Josef Cinibulk
Veronika Grunwaldova
Hana Brusova
Original Assignee
Zentiva Ks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva Ks filed Critical Zentiva Ks
Publication of MX2012002621A publication Critical patent/MX2012002621A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
MX2012002621A 2009-09-02 2010-09-02 Un metodo de cristalizacion de clorhidrato de (s)-n-metil-3-(1-naftiloxi)-3-(2-tienil)propilamina (duloxetina). MX2012002621A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2009-584A CZ304602B6 (cs) 2009-09-02 2009-09-02 Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)
PCT/CZ2010/000099 WO2011026449A1 (en) 2009-09-02 2010-09-02 A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine)

Publications (1)

Publication Number Publication Date
MX2012002621A true MX2012002621A (es) 2012-07-03

Family

ID=43413356

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002621A MX2012002621A (es) 2009-09-02 2010-09-02 Un metodo de cristalizacion de clorhidrato de (s)-n-metil-3-(1-naftiloxi)-3-(2-tienil)propilamina (duloxetina).

Country Status (11)

Country Link
EP (1) EP2473497A1 (cs)
JP (1) JP2013503823A (cs)
KR (1) KR20120047262A (cs)
CN (1) CN102482254A (cs)
BR (1) BR112012004862A2 (cs)
CZ (1) CZ304602B6 (cs)
EA (1) EA021528B1 (cs)
IL (1) IL218329A0 (cs)
MX (1) MX2012002621A (cs)
WO (1) WO2011026449A1 (cs)
ZA (1) ZA201201570B (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626735A (zh) * 2012-08-28 2014-03-12 石药集团中奇制药技术(石家庄)有限公司 一种盐酸度洛西汀晶型及其制备方法
CN104478849A (zh) * 2014-02-14 2015-04-01 广东东阳光药业有限公司 制备去甲肾上腺素再摄取双重抑制剂的方法
CN106265528A (zh) * 2015-05-12 2017-01-04 法德生技药品股份有限公司 制备药物凝集体的方法
JP2016222628A (ja) * 2015-06-03 2016-12-28 株式会社トクヤマ デュロキセチン塩酸塩の製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880007433A (ko) 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
DE10212301A1 (de) 2002-03-20 2003-10-02 Bayer Ag Verfahren zur Herstellung von Aryl-aminopropanolen
PT1539673E (pt) 2002-07-09 2007-11-14 Lonza Ag Processo para preparação de beta-aminoálcoois nmonossubstituídos
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
CZ297560B6 (cs) * 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
EP1858859A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Process for the preparation of optically active (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation
GB0612509D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
GB0612508D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
CZ300116B6 (cs) * 2006-12-05 2009-02-11 Zentiva, A. S. Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
US8269023B2 (en) * 2007-03-05 2012-09-18 Lupin Ltd. Process for preparation of duloxetine hydrochloride

Also Published As

Publication number Publication date
CZ2009584A3 (cs) 2011-03-09
EP2473497A1 (en) 2012-07-11
ZA201201570B (en) 2013-08-28
EA021528B1 (ru) 2015-07-30
BR112012004862A2 (pt) 2015-09-08
JP2013503823A (ja) 2013-02-04
WO2011026449A1 (en) 2011-03-10
EA201290127A1 (ru) 2013-02-28
CN102482254A (zh) 2012-05-30
IL218329A0 (en) 2012-04-30
CZ304602B6 (cs) 2014-07-30
KR20120047262A (ko) 2012-05-11

Similar Documents

Publication Publication Date Title
UY32407A (es) Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino
MX2012002621A (es) Un metodo de cristalizacion de clorhidrato de (s)-n-metil-3-(1-naftiloxi)-3-(2-tienil)propilamina (duloxetina).
MX350121B (es) Derivados de n-(3-carbamoilfenil)-1h-pirazol-5-carboxamida y el uso de los mismos para el control de plagas de animales.
BRPI0912907A2 (pt) "suspensão de aveia, composição, processo para a preparação de uma suspensão de aveia, pó e composição comestível não-láctea"
NZ700620A (en) Apparatus and method for rapidly charging batteries
EP2555287A4 (en) POSITIVE ELECTRODE MATERIAL FOR A LITHIUM SUBSTANCE BATTERY, METHOD OF MANUFACTURING THEREOF, POSITIVE ELECTRODE FOR A LITHIUM SUBSTANCE BATTERY AND LITHIUM SUBSTANCE BATTERY
EP2744248A4 (en) METHOD AND DEVICE FOR INDICATING THE CAPACITY OF A FINISHING DEVICE
IL230600A (en) Method for Preparing 4 - (Pipridine - 1 - Il) - Benzo [b] Theophane and its History
ZA200807263B (en) Novel heteroaryl-substituted arylaminopyrldine derivatives as MEK inhibitors
AU2012204481A8 (en) Selecting storage locations for storing data based on storage location attributes and data usage statistics
AP3381A (en) Method and apparatus for charging an upwardly oriented hole with a pumpable
GB0712788D0 (en) Clock frequency adjustment within an SoC
MX2013011194A (es) Ahorro de energia adapatable para una unidad de suscriptor movil en una red de comunicacion inalambrica.
MX352470B (es) Disales de acido malonico y metodo para preparar dihaluros de malonilo.
EP2455924B8 (en) Wireless provision of electricity metering data from an electricity charging event
TW200635913A (en) Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
EP2896249A4 (en) REDUCTION OF PERFORMANCE CONSUMPTION AND TIME FOR TOF POSITIONING OVER A NEIGHBOR LIST
EA201270790A1 (ru) Соединение пиперидинила в качестве модулятора активности хемокинового рецептора
EP2610674A4 (en) METHOD FOR PRODUCING A CARRIAGE CORE FOR ELECTRO-PHOTOGRAPHIC DEVELOPERS, SUPPORTING CORE FOR ELECTRO-PHOTOGRAPHIC DEVELOPERS, SUPPORT FOR ELECTRO-PHOTOGRAPHIC DEVELOPERS AND ELECTRO-PHOTOGRAPHIC DEVELOPER
GB0504889D0 (en) Management of tracking models suitable for demanding defence scenarios
EA201000398A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
FR2968272B1 (fr) Element de structure ameliore d'un giravion pour diminuer la trainee aerodynamique.
WO2013015530A3 (ko) 호두공급장치
WO2008081476A3 (en) Process for preparing duloxetine hydrochloride
MX337997B (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal